Kindred Biosciences (KIN) Misses Q4 EPS by 2c

Kindred Biosciences (NASDAQ: KIN) reported Q4 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.26 million.

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c